OBJECTIVES: Subclinical vascular disease (SVD) contributes to the aging process and may decrease life expectancy. We aimed to determine the contribution of gradations of SVD to the likelihood of achieving longer survival, and to determine what allows some individuals to achieve longer survival in the presence of high SVD.
INTRODUCTION
Subclinical vascular disease (SVD), which may never cross the threshold of clinically recognized disease, contributes to health status and can increase the risk of disability and death. (1) Although it is accepted that high SVD is associated with morbidity and mortality, (2) whether low SVD is associated with longer survival has not been adequately described. The majority of research on determinants of longer survival has examined traditional risk factors and lifestyle factors, and has not included subclinical disease. (3) (4) (5) Subclinical changes may help explain the wide range in survival observed in aging that is not completely explained by clinically recognized disease.
In the Cardiovascular Health Study (CHS), we have observed the phenomenon of persons in whom subclinical and clinical vascular disease accumulates well beyond the threshold for high
risk, yet such individuals continue to survive to very old age. By describing the characteristics of these individuals, we may identify factors that could modify the potential harm of SVD. It is these protective factors that may provide the most advantageous foundation for crafting interventions to promote longer survival, because they may decrease risk of disability and death even in high-risk individuals.
We examined if gradations of SVD are associated with longer survival, assessed by
Subclinical Vascular Disease
The SVD index was assessed by the same method as in a previous CHS publication (2) ; this index better captures low levels of disease and high vascular health compared with traditional indices that only capture high levels of disease. Briefly, three measures of subclinical vascular health were assessed at the 1992-1993 visit: ankle-arm index (AAI), electrocardiogram (ECG), and common carotid ultrasound. Each measure was scored as 0, 1, or 2 indicating no, minor, or severe abnormalities. AAI was classified as low risk (>1.0 to 1.4), moderate risk (>0.9 to 1.0 or >1.4), high risk (≤0.9), based on previous research in the CHS.(7) ECG findings were classified based on standardized criteria in the CHS, and were categorized as no, minor (minor Q or QS waves, high R waves, minor isolated ST-T abnormalities, ST elevation, incomplete right bundle branch block, long QT interval, short PR, right axis deviation), or major abnormalities (ventricular conduction defects, major Q or QS abnormalities, minor Q or QS with ST-T wave abnormalities, left ventricular hypertrophy, isolated major ST-T, wave changes, atrial fibrillation or first-degree atrioventricular block).(8) Common carotid artery intima-media thickness (IMT) was classified as <0.905 mm, ≥0.905 mm to 1.218 mm to, or > 1.218 mm corresponding to the lowest quintile (most healthy), middle three quintiles, and upper quintile (least healthy).
Other Measures
Age was calculated as the difference between the visit date and the date of birth from the Medicare eligibility lists. Sex, education, and race were determined by self-report; race was categorized as black or white/other because <1% of participants self-identified as not of black or white race. Smoking history, alcohol consumption, and total physical activity (kcal/week) were assessed by standardized interview. Height, weight, and blood pressure were measured by standard protocol. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Total and high-density lipoprotein (HDL) cholesterol were measured in fasting blood samples. Diabetes was defined according to previous ADA guidelines as a fasting glucose ≥126 mg/dL or use of insulin or hypoglycemic medications, and impaired fasting glucose if glucose ≥110mg/dL and <126 mg/dL.(9) Cystatin C was measured by a BNII nephelometer (Seimens Healthcare Diagnostics, Deerfield, IL) that utilizes a particle enhanced immunonepholometric assay (N Latex Cystatin-C) (10). C-reactive protein (CRP) was measured in plasma by a high sensitive immunoassay. Depressive symptoms were assessed by a modified 10-item Center for Epidemiologic Studies Short Depression Scale (CES-D). Frailty was assessed by a modified scale which includes unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low physical activity, and has a more normalized distribution and less of a ceiling effect compared with the traditional Fried frailty index.(11, 12) Participants were asked about medication use and were asked to bring their medications to clinical visits. (13) Clinical cardiovascular disease was defined as a history of myocardial infarction, angina, revascularization, peripheral vascular disease, heart failure, transient ischemic attack, or stroke; CHS participants were classified at baseline by a combination of hospital records and physician confirmation, and all incident events were adjudicated by a CHS outcome-assessment committee. (14) 
Statistical Analysis
We described risk factors across survival groups and tested for linear trend. We compared the characteristics of participants with a higher burden of SVD (index score ≥4) who lived to age 85 or older (adapters) with those who died before age 85 (expected) using chi-squared tests for categorical risk factors and analysis of variance for continuous measures.
Ordered logistic regression models were used to assess the association between SVD (independent variable) and survival group (dependent variable), after adjustment for risk factors.
This method estimates the proportional odds and assumes that the odds ratio is constant across any greater age groups, compared to any age group below (i.e. survival to ≥90 years versus <90 years, ≥85 years versus <85 years, or ≥80 years versus <80 years). The association was initially adjusted for clinical vascular disease status at baseline, age, sex and race. A fully adjusted model added education, alcohol consumption, alcoholic drinks in the last week, diabetes status (normal/IFG/diabetes), pack-years, BMI, ln(physical activity), systolic blood pressure, diastolic blood pressure, HDL cholesterol, total cholesterol, depressive symptoms, frailty score, ln(cystatin-C), ln(CRP), and use of aspirin or lipid lowering medications. We next examined whether adjustment for intermediate incident CVD events attenuated the association between SVD and longer survival, and we conducted the models of SVD and longer survival in persons free of CVD at baseline. Additionally we examine the association between SVD and the age at time of CVD event (≤75, 76-80, 81-84, 85+, never), also based on ordered logistic regression models. Models were assessed for violations of the proportional odds assumption. In order to determine whether other factors modified the risk of subclinical disease on longer survival, we Subclinical Vascular Disease and Survival 9 tested interactions of the subclinical disease index with the following a priori factors in the demographic-adjusted model: smoking status, physical activity, BMI, and frailty score, as well as those factors that differed across the adaptors and expected groups. Factors with interaction terms with a p-value of <0.1 were explored further in stratified models.
All analyses were conducted using Stata 11.0 (StataCorp, College Station, TX) and R 2.15 (The R Foundation, Vienna, Austria).
RESULTS
At the 1992-1993 visit, the mean age of the participants was nearly identical in women were aged 90-95, as determined by the birth cohort restrictions. On average, participants who achieved longer survival were less often male, had more education, were less likely to smoke, and had lower total pack years of smoking compared to those who died at younger ages. (Table   1 ) Those who achieved longer survival were likely to be more physically active, and have higher total and HDL cholesterol, and lower systolic blood pressure, CRP, and cystatin C levels.
Participants reaching longer survival also had lower levels of depressive symptoms and frailty, and were more likely to be free of diabetes and CVD, and had lower rates of incident CVD.
( Table 1) Approximately 50% of people with no clinical or subclinical CVD, or a SVD index score of 1 lived to age 90 or older, whereas less than 20% of persons with a SVD score of ≥4 or clinical CVD achieved this milestone ( Figure 1 ). Overall, there was a graded association between the level of SVD and the proportion of participants achieving longer survival (p<0.01 for all trends). Persons with no abnormalities on each of the component measures of SVD (AAI, ECG, common carotid IMT) were more likely to live to older age compared with persons with minor or severe abnormalities (Supplemental Table 1 ).
Persons with longer survival had a lower incidence rate of CVD events. (Figure 2 )
Persons achieving survival to age 90 and older had less than half the rate of incident CVD compared to those living to less than 80 years. There was an association between SVD and incident rate of CVD, and the grade of the association was much stronger in those participants living to less than 80 years. (Figure 2 )
We compared the characteristics of participants with a higher burden of SVD (index score ≥4) who lived to age 85 or older (adapters) and those who died before age 85 (expected) ( Table 2 ). The adapters were less often men, were less likely to have ever smoked, and had fewer pack years of smoking. Adapters also had lower levels of cystatin C, depression, frailty, diabetes, and prevalent and incident CVD. (Table 2) Based on a proportional odds model, the odds of achieving longer survival (≥90 years versus <90 years, ≥85 years versus <85 years, or ≥81 years versus <81 years) was 1.35 (95% CI:
1.27, 1.44) higher for each point lower of the SVD index. (Table 3 ) This estimate was nearly identical when we restricted the study population to those free of CVD at baseline (n=1,519):
1.34 (95% CI: 1.25, 1.45). The association of one point lower SVD and longer survival persisted after adjustment for potential confounders (OR = 1.22, 95% CI: 1.14, 1.31). (Table   3 )Surprisingly, adjustment for intermediate CVD events did not affect the estimates for the associations of SVD and longer survival. (Table 3 ) Lastly, the association between a one point lower of the SVD index and age at incident CVD was 1.32 (95% CI: 1.21, 1.41) in demographicadjusted models and 1.24 (95% CI: 1.14, 1.35) after adjustment for potential confounders.
The low risk group of each of the components of the SVD index was strongly and consistently associated with longer survival compared with the high risk group in demographic adjusted models. Supplemental Table 2 ) Adjustment for potential confounders had a modest impact on the estimates for the SVD measures, and rendered the moderate risk groups no longer statistically significantly different compared with the high risk groups.
Only ln(cystatin C) was observed to have a statistically significant interaction with SVD index score (p=0.04) in models adjusted for age, sex, race, and baseline CVD status. In persons with worse kidney function, the association of SVD index score and longer survival was modestly stronger. For example, among persons with a cystatin C of 1.0 mg/dL the odds ratio of a 1 point lower SVD index score was 1.31 (95% CI; 1.23, 1.41); whereas it was 1.75 (95% CI:
1.34, 2.27) in someone with a cystatin C of 2.72 mg/dL (one unit higher ln cystatin C).
Additionally, there was a trend towards an interaction with smoking status (never vs. ever, p=0.07) and ln(CRP) (p=0.08); the association of SVD and longer survival appeared modestly stronger in persons with a history of smoking or higher levels of CRP. The odds ratio for a one point lower SVD index score among participants who never smoked was 1.25 (95% CI: 1.13, 
DISCUSSION
This is the first large-scale study of SVD and years of survival; nearly 700 men and women in a narrow birth cohort window lived to age 90 years or older, offering a unique opportunity to evaluate factors that may enable elders to reach this age. In this investigation, we observed a strong and graded relationship between lower burden of SVD and longer survival. contribute to the probability of achieving longer survival. In contrast, a good cardiovascular risk profile explains much of the variance in years of survival, so the remaining variance due low SVD would be less, and therefore result in a weaker association between low SVD and longer survival. These findings suggest that these protective factors may be important targets for intervention, especially in persons who are the most vulnerable. While achieving therapeutic targets for multiple cardiovascular risk factors is paramount, our findings suggest that capitalizing on targeted opportunities for intervention may preserve health and extend years of survival.
Our study has limitations that should be considered. We restricted the study population to a birth cohort of CHS participants born after June 30th, 1918 and before June 30th, 1921. While these birth year restrictions minimized any confounding by age and birth cohort, this also limits the generalizability of the findings. Additionally, the differences we observed in risk and protective factors across adapters and those with expected years of survival were modest, and only the interaction between SVD and cystatin C reached statistical significance in models adjusted for age, sex, race, and baseline clinical CVD status. Interactions require more statistical power to identify with precision compared to main effects, and the increased variability of measures observed at older ages may further limit this power. The patterns observed are intriguing and should be further explored in other investigations, although we cannot exclude the possibility that these findings may have been due to chance.
In summary, we show that lower scores on a SVD index are associated with longer survival. Individuals who reach their 70's with a low burden of vascular disease are very likely to achieve survival to age 90. Clinically, they are good candidates for preventive measures targeting disability prevention, such as prevention of falls, fractures, cancer, arthritis, and dementia. Our study also suggests abstinence from smoking, better kidney function, and lower inflammation may buffer the adverse effects of a high burden of vascular disease. Further investigations into factors that allow older adults to achieve exceptional health and longer survival in the presence of a high burden of disease will help guide the development of interventions which may be most beneficial for mitigating the effects of vascular disease and promoting long life. 
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